Gitr, Inc.

Also on record

Records under this name other than patents Gitr, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Showing 1 to 8 of 8 · Back to Gitr, Inc.

Patent	Title	Status	Expires	Confidence
US 7,812,135	Gitr-Binding Antibodies Term ended Term ended Mar 27, 2026 · High confidence	Term ended	Term ended Mar 27, 2026	High confidence
US 10,030,074	Methods of Inducing or Enhancing an Immune Response in a Subject Having Cancer by Administering Gitr Antibodies Term ended Term ended Mar 27, 2026 · Medium confidence	Term ended	Term ended Mar 27, 2026	Medium confidence
US 8,591,886	Combination therapies employing GITR binding molecules Lapsed on the fee record Ended Nov 26, 2025 · From the USPTO record	Lapsed on the fee record	Ended Nov 26, 2025	From the USPTO record
US 9,493,572	Gitr Antibodies and Methods of Inducing or Enhancing an Immune Response Lapsed on the fee record Ended Nov 15, 2024 · Medium confidence	Lapsed on the fee record	Ended Nov 15, 2024	Medium confidence
US 10,570,209	Methods For Inducing Or Enhancing An Immune Response By Administering Agonistic Glucocorticoid-Induced TNFR-Family-Related Receptor (GITR) Antibodies Lapsed on the fee record Ended Feb 25, 2024 · High confidence	Lapsed on the fee record	Ended Feb 25, 2024	High confidence
US 9,241,992	Combination therapies employing GITR binding molecules Lapsed on the fee record Ended Jan 26, 2024 · From the USPTO record	Lapsed on the fee record	Ended Jan 26, 2024	From the USPTO record
US 9,028,823	Methods of Inducing or Enhancing an Immune Response in a Subject by Administering Agonistic Gitr Binding Antibodies Lapsed on the fee record Ended May 12, 2023 · Medium confidence	Lapsed on the fee record	Ended May 12, 2023	Medium confidence
US 8,388,967	Methods for inducing or enhancing an immune response by administering agonistic GITR-binding antibodies Lapsed on the fee record Ended Mar 5, 2021 · High confidence	Lapsed on the fee record	Ended Mar 5, 2021	High confidence